News and Events

Brussels, 23 September 2024 – Synergia Medical, a leader in the development of optoelectronic medical devices, is pleased to announce the successful implantation of its groundbreaking NAO.VNS system in the first two patients as part of the AURORA study. These first-in-human implantations took place on September 6, 2024, at Cliniques Universitaires Saint-Luc and UZ Gent. Two weeks after surgery, both patients have fully recovered, allowing the initiation of stimulation therapy as planned.

Synergia Medical is pleased to announce that they have been awarded the Prix Galien 2023 in Belgium for promising medical devices.

Synergia Medical announced the appointment of Dan Scherrer as Chief Operating Officer. Dan Scherrer brings over 20 years of experience manufacturing, supply chain, quality management and product development in the medical device field. 

Synergia Medical announced the successful completion of a €9 million Series B funding round. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2023 and the IDE (Investigational Device Exemption) submission to the FDA in the USA. IDE allows an investigational device to be used in a clinical study to collect safety and efficacy data.

Synergia Medical is proud to announce the renewal of its ISO 13485 – Medical Devices – Quality Management System certification.

Synergia Medical is proud to have been selected as one of the 5 finalists of the 9th Annual Shark Tank Competition organized by the Epilepsy Foundation.

Synergia Medical proudly announces the appointment of Mrs. Sophie Baratte as Chair of the Board.